drugset / Trial / NCT07309289
NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To explore the safety and efficacy of NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer.
Timeline
- Start
- 2025-07-01
- Primary completion
- 2029-03-01
- Completion
- 2029-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 50 mg/m2 | Intravenous |
| Comparator | Oxaliplatin | Small molecule | 75 mg/m2 | Intravenous |
| Comparator | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Comparator | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Comparator | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Comparator | FOLFOX plus targeted therapy | Unknown | 400 mg/m2 | Intravenous |
| Background | NALIRIFOX plus targeted therapy | Unknown | 400 mg/m2 | Intravenous |
| Comparator | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |
| Background | l-LV | Unknown | 200 mg/m2 | Intravenous |
| Comparator | l-LV | Unknown | 200 mg/m2 | Intravenous |